Literature DB >> 9756328

Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.

F C Cheng1, D R Ni, M C Wu, J S Kuo, L G Chia.   

Abstract

To mimic chronic exposure to neurotoxins in inducing dopaminergic cell damage, multiple doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were injected in C57BL/6 mice. Effects of pre- and post-treatment with the glial cell line-derived neurotrophic factor (GDNF) by injections into the striatum were investigated. GDNF exerts protective and reverse effects on the dopaminergic damage, supporting the potential application of GDNF in prevention and treatment of Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9756328     DOI： 10.1016/s0304-3940(98)00554-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN： 0304-3940            Impact factor:   3.046


  9 in total

1.  CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice.

Authors:  Mikko Airavaara; Brandon K Harvey; Merja H Voutilainen; Hui Shen; Jenny Chou; Päivi Lindholm; Maria Lindahl; Raimo K Tuominen; Mart Saarma; Barry Hoffer; Yun Wang
Journal:  Cell Transplant       Date:  2011-09-22       Impact factor: 4.064

Review 2.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity.

Authors:  Bin Xing; Tao Xin; Lingling Zhao; Randy L Hunter; Yan Chen; Guoying Bing
Journal:  J Neuroimmunol       Date:  2010-05-14       Impact factor: 3.478

4.  Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration.

Authors:  Yuen-Sum Lau; Gaurav Patki; Kaberi Das-Panja; Wei-Dong Le; S Omar Ahmad
Journal:  Eur J Neurosci       Date:  2011-03-07       Impact factor: 3.386

Review 5.  Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.

Authors:  Yossef S Levy; Merav Stroomza; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

6.  Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  O Eberhardt; R V Coelln; S Kugler; J Lindenau; S Rathke-Hartlieb; E Gerhardt; S Haid; S Isenmann; C Gravel; A Srinivasan; M Bahr; M Weller; J Dichgans; J B Schulz
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

7.  Heterotopic mucosal engrafting procedure for direct drug delivery to the brain in mice.

Authors:  Richie E Kohman; Xue Han; Benjamin S Bleier
Journal:  J Vis Exp       Date:  2014-07-16       Impact factor: 1.355

8.  Resveratrol Produces Neurotrophic Effects on Cultured Dopaminergic Neurons through Prompting Astroglial BDNF and GDNF Release.

Authors:  Feng Zhang; Yan-Ying Wang; Hang Liu; Yuan-Fu Lu; Qin Wu; Jie Liu; Jing-Shan Shi
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-28       Impact factor: 2.629

Review 9.  Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice.

Authors:  Venissa Machado; Tanja Zöller; Abdelraheim Attaai; Björn Spittau
Journal:  Int J Mol Sci       Date:  2016-01-26       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.